Feds Struggle to Collect $452M Theranos Debt From Holmes
It is 2026, and the federal government is still trying to wring blood from a stone. The stone, in this case, is Elizabeth Holmes and her former partner, Ramesh “Sunny” Balwani. The price tag? A staggering $452 million.
Years after the spectacular collapse of their blood-testing startup, Theranos, the criminal trials are long over. Both Holmes and Balwani are locked away in federal prisons. Yet the financial fallout of their massive fraud remains a messy, slow-moving disaster. The Department of Justice is discovering that winning a massive restitution order in court is easy compared to actually collecting the cash.
The Multi-Million Dollar Deficit
The math is brutal. In 2023, U.S. District Judge Edward Davila ordered Holmes and Balwani to jointly pay $452,047,268 to their victims. The list of people they owe reads like a registry of American wealth. Media tycoon Rupert Murdoch lost $125 million. The DeVos family, led by former Education Secretary Betsy DeVos, lost $100 million. Walgreens and Safeway lost tens of millions more in failed retail partnerships.
But the money is gone. It was burned through during Theranos’s rapid expansion, spent on luxury lifestyles, or eaten up by millions of dollars in legal defense fees.
Holmes, currently serving her sentence at a federal prison camp in Bryan, Texas, has repeatedly claimed she is broke. Her lawyers have fought almost every government attempt to set up a structured payment plan. They argue she has no assets left and no prospects of earning money while behind bars. Her projected release date is in the early 2030s, though good behavior could shave off some time.
Fighting Over Pennies
The legal fight has turned petty. Last year, prosecutors and defense attorneys clashed over a proposed payment plan for when Holmes is finally released. The government wanted her to pay $250 each month, or 10% of her gross income, whichever is greater. Holmes’s team balked. They argued that she would have no job, three young children to support, and zero financial stability upon release. They called the government’s demands unjust.

While in prison, Holmes has been paying a nominal fee. Under the Treasury Department’s Inmate Financial Responsibility Program, she has paid as little as $25 every three months. At that rate, it would take her millions of years to settle her debt.
“The government is playing a long game here,” says David Greenfield, a white-collar defense attorney who has watched the case unfold. “They know they will never see the full $452 million. That is a fantasy. But they want to establish a precedent. If Holmes ever writes a memoir, signs a movie deal, or gets a high-paying consulting gig after she gets out, the feds want to make sure she doesn’t keep a dime of it.”
The Long Hunt for Balwani’s Assets
Balwani’s situation is slightly different. Unlike Holmes, who built her entire career on Theranos, Balwani was already a wealthy man before he joined the company. He made a fortune during the dot-com boom of the late 1990s. Because of this, the government has had a slightly easier time targeting his personal holdings.
Federal agents have moved to seize his real estate, bank accounts, and stock portfolios. But even these seizures represent a tiny fraction of the half-billion-dollar debt. Balwani, who is serving his sentence at a federal facility in San Pedro, California, continues to challenge the aggressive collection efforts through his legal team.
The Reality for the Victims
For the wealthy investors who backed Theranos, the lack of restitution is mostly a blow to their pride. Most of them wrote off the losses years ago. But for the patients who received inaccurate blood tests—some of whom were falsely led to believe they had cancer or prostate issues—the lack of compensation feels like a double standard.
As 2026 rolls on, the paper chase continues. The court filings keep piling up. Every few months, there is another minor adjustment to the payment schedules, another motion filed, another brief argued. The grand Theranos saga, which began with promises of changing medical science forever, has devolved into a tedious bureaucratic battle over dollars that simply do not exist.